Fig. 2: C16 in combination with Ang-1 treatment alleviated the synchronous contraction of muscles. | npj Parkinson's Disease

Fig. 2: C16 in combination with Ang-1 treatment alleviated the synchronous contraction of muscles.

From: Adjusting vascular permeability, leukocyte infiltration, and microglial cell activation to rescue dopaminergic neurons in rodent models of Parkinson’s disease

Fig. 2

Compared with the normal control group (a, b), MPTP-injected mice showed synchronous contraction of agonist and antagonist muscles in both lower limbs, as measured by the wave amplitude (uV) (c, d). The antagonist muscle of the model animals treated with C16 alone (e, f), Ang-1 alone (g, h), and especially the combination of C16 and Ang-1 (i, j) did not contract with the agonist muscles synchronously after stimulation. MPTP, 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine; C16, peptide (KAFDITYVRLKF) that can selectively bind integrin ανβ3; Ang-1, angiopoietin-1.

Back to article page